PBD Biotech

PBD Biotech Ltd. has developed a novel phage-based technology, which is able to sensitively detect the presence of live bacteria in blood or milk.

Its patented Actiphage products include a blood test, to aid early detection of bovine TB and Johne’s disease, and a milk test for quality assurance of dairy products. The technology is able to deliver results within six hours. As opposed to the number of weeks it takes current detection methods.

Unlike the existing gold-standard tests for mycobacterial diseases, which analyse the immune response of the animal, PBD Biotech’s Actiphage test directly measures the presence of live bacteria.

Originally developed for human tuberculosis, Actiphage has been refined for veterinary and food processing applications. Actiphage has been successfully used to detect live mycobateria in raw milk, pasteurised milk, powdered infant formula, cheese and in the blood of infected animals. The highly sensitive and specific test has been applied to samples from 17 species so far, including cattle, camelids and exotic animals.

In May 2018, the test was approved by the Animal & Plant Health Agency (APHA) for Exceptional Private Use by cattle farmers suffering chronic TB breakdowns in England. Other international trials are underway.

Member's Area/s of Interest

Technology

Being members of Agri-Tech East is a massive asset for a start-up company in this sector and is already creating a hugely valuable impact for our company.

As a start-up company with little experience in the agri-tech sector, PBD Biotech considers itself hugely fortunate to be located in East Anglia. When we first started out – although the business plan was well advanced, the technology validated and ready for prototype manufacture – there were major gaps in terms of seeking seed finance in the sector, networking with other commercial partners and understanding the regulatory processes.

Having joined Agri-Tech East, Belinda and Becky opened numerous doors to local investors including the Eastern Agri-Tech Growth Fund and introduced us to a network of relevant bodies including the NFU and regulatory advisors with a common interest in the improved control of mycobacterial disease in agriculture.

Moreover, the opportunity to present at networking events such as REAP allowed us to really maximise PR opportunities that have had a startling impact on an early phase business.

Dr Berwyn Clarke, CEO

PBD Biotech secures £2.3m funding for OIE validation of its rapid, accurate bovine TB test

PBD Biotech has secured a £2.3m investment to take Actiphage through to validation by the World Organisation for Animal Health (OIE). Full validation will enable international adoption of this novel, patented, diagnostic for mycobacterial diseases, which include human tuberculosis and Johne’s Disease.

Top innovation award for Actiphage, rapid tuberculosis test

Actiphage®, a rapid, accurate test for tuberculosis that detects the presence of the live mycobacteria in a sample of blood or milk, has been awarded the Innovation Award 2021 by the British Veterinary Association (BVA).

PBD Biotech’s rapid new Actiphage test for human and animal diseases progresses in Canada

Johne’s disease costs the Canadian dairy industry an estimated $90 million a year through loss of production. Now, advisory services and funding from NRC IRAP is enabling PBD Biotech to further research and progress development of its unique Actiphage® diagnostic for hard-to-detect mycobacterial diseases, such as Johne’s.

As bovine TB reaches record levels in Wales permission is given for first trial of PBD Biotech’s Actiphage® blood test

Vet Robert Price-Jones comments in a BBC interview that the blood test Actiphage offers the potential for eradicating bovine TB from the farm: “Early identification of animals at risk of bovine TB enables effective disease management and control.”

PBD Biotech

Member's Area/s of Interest

PBD Biotech secures £2.3m funding for OIE validation of its rapid, accurate bovine TB test

Top innovation award for Actiphage, rapid tuberculosis test

Actiphage®, a rapid, accurate test for tuberculosis that detects the presence of the live mycobacteria in a sample of blood or milk, has been awarded the Innovation Award 2021 by the British Veterinary Association (BVA).

PBD Biotech’s rapid new Actiphage test for human and animal diseases progresses in Canada

As bovine TB reaches record levels in Wales permission is given for first trial of PBD Biotech’s Actiphage® blood test

Vet Robert Price-Jones comments in a BBC interview that the blood test Actiphage offers the potential for eradicating bovine TB from the farm: “Early identification of animals at risk of bovine TB enables effective disease management and control.”

Actiphage test wins UK Royal Dairy Innovation Award 2019

PBD Biotech’s Actiphage technology wins Royal Dairy Innovation Award 2019

Interest in Actiphage diagnostic from world leading milk industry

PBD Biotech takes test for animal and public health to India in UK Government trade delegation.

PBD Biotech secures grant of key patent for new bacterial diagnostic technology

Actiphage, the novel diagnostic technology developed by PBD Biotech, has secured its unique IP from the European Patent Office

APHA grants access to new Actiphage technology for chronic TB breakdowns

UK Government publishes protocol permitting 'exceptional private use' of Actiphage 6-hour test on TB stricken herds in England

New research explains MAP found in pasteurised milk

New research shows phage-based test is able to rapidly identify low levels of live mycobacteria in pasteurised milk

Revolutionising livestock disease management

Considering new testing for Bovine TB.

Add a description for the members post

Agri-TechE on Twitter

Agri-TechE on Facebook

MORE INFORMATION

© Agri-TechE 2020

Site design by Out of House